Nicholas Kallas, Ph.D., has over 30 years of patent law experience, focusing primarily on patent litigation and pre-suit investigations in matters related to pharmaceuticals, chemicals, food and consumer products. Clients recognize Nick’s commitment, knowledge, and professionalism, noting that he “consistently does an excellent job” (Client Report Card 2014). It is no wonder then that clients who have worked with Nick “for 20 years  would refer him and his firm without hesitation.” (U.S. News – Best Lawyers 2010-11). Nick has significant trial and appellate experience, often serving as lead trial counsel, and brings that experience to bear in how he handles cases.
Specific technologies Nick has worked with include anti-fungal, herpes, breast cancer, osteoporosis, anti-cholesterol, ophthalmic, anti-cholinesterase, and immunosuppressant drugs; microemulsion, enteric coating, and delayed release pharmaceutical formulations; and crystalline drug products.
Novartis Pharmaceuticals Corporation et al v. Noven Pharmaceuticals Inc.
D. Del. (2015)
Nick secured an affirmance by the Federal Circuit in a Hatch-Waxman litigation concerning Novartis’s Exelon® Transdermal Patches for the treatment of Alzheimer’s Disease. The Federal Circuit agreed that because the stability problem was not known, one of ordinary skill would not have been motivated to fix it.